Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?

File(s)

Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma.docx (47.93 KB)

Accepted version

Show more

Author(s)

Badi, Yusef

Pavel, Ana B

Riley, John H

Chung, Kian F

Guttman-Yassky, Emma

more

Type

Journal Article

Date Issued

2019-09-28

Date Acceptance

2019-03-05

Citation

EUROPEAN RESPIRATORY JOURNAL, 2019, 54

URI

http://hdl.handle.net/10044/1/76957

DOI

https://www.dx.doi.org/10.1183/13993003.congress-2019.OA1606

ISSN

0903-1936

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD

Journal / Book Title

EUROPEAN RESPIRATORY JOURNAL

Volume

54

Copyright Statement

Copyright the authors

Sponsor

Commission of the European Communities

Identifier

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000507372400027&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Grant Number

115010

Subjects

Science & Technology

Life Sciences & Biomedicine

Respiratory System

Asthma

Severe asthma

Genomics

Publication Status

Published

Coverage Spatial

Madrid, SPAIN